linjc16/ctgov huggingface dataset:
A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells

Study Overview
=================
Brief Summary
-----------------
This is a single center, single arm and open-label study to investigate the safety and efficacy of iPS-NCS with Parkinson's Disease

Official Title
-----------------
Clinical Study of the Safety and Efficacy of Autologous Neural Stem Cells in the Treatment of Parkinson's Disease

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Drug: Ips-nsc cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject is able to understand the research requirements, provide written informed consent, and complete the study in accordance with the procedures; The subject is clearly diagnosed with Parkinson's; Recorded disease progression over the past 6 months; Vital organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥ 50%, no obvious abnormality in ECG; blood oxygen saturation ≥ 90%; creatinine clearance calculated by Cockcroft-Gault formula ≥ 40ml/min; ALT and AST ≤ 3 times the normal range, total bilirubin ≤ 2.0 mg/dl; Blood routine: Hgb≥80g/L, ANC≥1×109/L, PLT≥50×10/L; Exclusion Criteria: Mental illness or a neurological disease not associated with Parkinson's disease; Serious other concomitant diseases (tumor, organ failure, etc.); Subjects used a large amount of corticosteroids, immunoglobulins, immunosuppressants before entering the study; Participated in other clinical trials of cell preparations and participated in other clinical trials within 3 months; There are already cognitive impairments or depressions, etc., and the research cannot be completed well; Female subjects who are breast-feeding or have a pregnancy plan recently.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ips-nsc treatment group<br> | Drug: Ips-nsc cells<br>* Total dose of ips-nsc cells will be administered at day0.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurrence of treatment related adverse events | occurrence of treatment related adverse events that are possible, likely. Or definitely related to study treatment. | 1 year |
Hemodynamic Effect of Prone Position in Non-intubated Patient With COVID 19

Study Overview
=================
Brief Summary
-----------------
Prone position in non-intubated patient has shown some respiratory physiological benefits. Prone positioning in patient intubated with ARDS has shown hemodynamic benefits. We aim to compare hemodynamic assessment before and after prone positioning in non-intubated patient with COVID 19 pneumonia. The study hypothesis is that prone positioning in non-intubated patient improve right ventricular preload, reduce afterload and increase Cardiac index compared to supine position.

Official Title
-----------------
Hemodynamic Effect of Prone Positioning in Non-intubated Patient With COVID 19 Pneumonia: a Monocentric Prospective Cohort Study

Conditions
-----------------
Covid19, Pneumonia, Viral

Intervention / Treatment
-----------------
* Procedure: prone position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient COVID 19 pneumonias with Hypoxemia for whom prone positioning has been decided by the attending physician. Exclusion Criteria: Mechanical ventilation ECLS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prone position in non-intubated COVID19 , before and after.<br>Patients with non-intubated COVID19 pneumoniae for whom the clinician has decided to try prone positioning to increase the PaO2 in a context of hypoxemia with O2 requirement. | Procedure: prone position<br>* Choice of prone positioning a patient is at the discretion of the anesthesia physician.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemodynamic effect | Cardiac index | Cardiac index will be recorded before, just after prone position and after return to supine position. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID 19, prone position, hemodynamic effect, spontaneous ventilation
Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study

Study Overview
=================
Brief Summary
-----------------
Aim of this study is to define the possible detrimental effect of a lack of growth hormone, on the well-being and life expectation of patients affected by heart failure.

Detailed Description
-----------------
Growth hormone and its main effector IGF-1 have well-documented roles in the regulation of cardiac and circulatory function. Evidence suggests that GH/IGF-1 exert a beneficial effect on cardiac load, cardiac growth and remodeling, despite their hypertrophying action. Several studies in the last years have demonstrated worse cardiovascular outcomes in adult patients with GH deficiency and/or low levels of IGF-1. A wide range of alterations in the GH/IGF-1 axis have been described to date in patients with chronic heart failure (CHF): reductions in GH levels, reductions in IGF-1 and a pattern of peripheral resistance to GH, in particular in patients with severe heart failure and cardiac cachexia. Our study hypothesis is that an actual status of GH deficiency coexists with CHF in a large percent of patients, and that it may represent a predictor of worse functional status and possibly of a worse prognosis. Aim of this study is to explore the latter hypothesis, comparing the clinical and functional evolution of patients with CHF and GHD with that of a general CHF population.

Official Title
-----------------
Observational Study on Prevalence and Prognostic Value of Growth Hormone Deficiency in Patients With Chronic Heart Failure

Conditions
-----------------
Ischemic Heart Disease, Cardiomyopathy, Heart Failure, Growth Hormone Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Heart Failure: NYHA class II to IV, ACC/AHA stage C/D Left ventricular end diastolic diameter >60 mm Left ventricular ejection fraction < 40% Clinical stability, guideline-oriented top pharmacological therapy Informed consent Exclusion Criteria: Active Myocarditis Hypertrophic Cardiomyopathy Active endocarditis Active malignancy End stage renal disease Severe liver disease (Child B-C)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GHD<br>Patients with Growth Hormone Deficiency | |
| non-GHD<br>Patients with CHF, without coexisting growth hormone deficiency | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart, failure, growth, hormone, igf, dilative, cardiomyopathy
Comparison of End-tidal Carbon Dioxide (ETCO2) Measured by Transportable Capnometer (EMMATM) and the Arterial pCO2 in General Anesthesia

Study Overview
=================
Brief Summary
-----------------
An end-tidal CO 2 monitor (capnometer) is used most often as a noninvasive substitute for PaCO2 in anesthesia, anesthetic recovery and intensive care. There is now also wide-spread use of capnometry on-site at emergency and trauma fields. So, portable device can be used usefully.

Conditions
-----------------
End Tidal Carbon Dioxide of Patients Undergoing General Anesthesia

Intervention / Treatment
-----------------
* Device: End-tidal CO2(portable capnometer)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who anticipated arterial gas analyze intraoperatively Exclusion Criteria: patients who didn't get arterial line

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: EMMA(TM)<br>A small capnograph for measuring ET-CO2 - the EMMA capnometer 1 | Device: End-tidal CO2(portable capnometer)<br>* End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.<br>* Other names: EMMA(TM );|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| End-tidal CO2 | End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling. | During operation (2-4 times) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
capnometer, end-tidal CO2
Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study

Study Overview
=================
Brief Summary
-----------------
Our overall objective is to model a pediatric Acute Asthma Clinical Decision Rule (ADR) for personalized medicine by identification of treatment-response phenotypes that are important determinants of outcome. The Specific Aim of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this DBRCT of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. Within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

Detailed Description
-----------------
The objective of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this DBRCT of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. Participants are randomized in randomly permuted blocks of four. Within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

Official Title
-----------------
Personalized Medicine, Biomarker-based Study of Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study

Conditions
-----------------
Acute Asthma

Intervention / Treatment
-----------------
* Drug: Albuterol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Doctor diagnosed asthma Acute asthma exacerbation Treatment with systemic corticosteroids and nebulized albuterol Ages 5 to 17 years Exclusion Criteria: Other acute or chronic lung disease

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Nebulized albuterol 10mg/hr continuous<br>Active control arm, 10mg/hr continuous. | Drug: Albuterol<br>* Nebulized albuterol<br>* Other names: proventil;|
| Experimental: 10mg/hr pulsed<br>Experimental 10mg/hr pulsed albuterol regimen. | Drug: Albuterol<br>* Nebulized albuterol<br>* Other names: proventil;|
| Experimental: 25mg/hr continuous<br>Experimental 25mg/hr continuous albuterol. | Drug: Albuterol<br>* Nebulized albuterol<br>* Other names: proventil;|
| Experimental: 25mg/hr pulsed<br>Experimental 25mg/hr pulsed albuterol | Drug: Albuterol<br>* Nebulized albuterol<br>* Other names: proventil;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| %FEV1 | % predicted forced expiratory volume in 1-second as a measure of airway obstruction | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Acute asthma, Pediatrics
Obstructive Sleep Apnea and Venous Thromboembolism

Study Overview
=================
Brief Summary
-----------------
There is a clear link between obstructive sleep apnea (OSA) and cardiovascular disease. However, there has been no clear link between OSA and venous thromboembolism (VTE). The objective of this study is to evaluate such a link.

Detailed Description
-----------------
Design: retrospective chart review of all patients with VTE over 10 year period retrospective chart review of all patients with OSA over 10 year period prospective 1 year follow up of all patients diagnosed with new VTE prospective 1 year follow up of all patients undergoing sleep study

Official Title
-----------------
Patients With Obstructive Sleep Apnea (OSA), Independent of Obesity, Are at Increased Risk of Venous Thromboembolic Events (VTE)

Conditions
-----------------
Obstructive Sleep Apnea, Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (>= 18 years) with sleep study, OSA or VTE Exclusion Criteria: Below 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VTE -PROSPECTIVE<br>Patients diagnosed with VTE | |
| sleep study group -PROSPECTIVE<br>patients undergoing sleep study | |
| VTE-Retrospective<br>patients with VTE , chart review | |
| OSA-retrospective<br>PATIENT WITH OSA -CHART REVIEW | |
| OSA group -PROSPECTIVE<br>patients diagnosed with OSA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of VTE for the OSA cohort |  | 12 months | 
| incidence of OSA for the VTE cohort |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  | 12 month | 
| bleeding |  | 12 months | 
| composite outcome of death, VTE , or bleeding |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive sleep apnea, venous thrombosis, pulmonary embolism, venous thromboembolism
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.

Official Title
-----------------
A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Drug: Ibuprofen
* Drug: celecoxib
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged >= 40 years old Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit Functional capacity class of I-III Exclusion Criteria: Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded) Acute joint trauma at index joint within the past 3 months with active symptoms Score of >=20 on PHQ-9 or score of >=1 on PHQ-9 item i Use of mobility assisting device for <6 weeks or use of walker

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ibuprofen<br> | Drug: Ibuprofen<br>* 800 mg oral tablet three time daily with meals for 6 weeks<br>|
| Experimental: Celecoxib<br> | Drug: celecoxib<br>* 200 mg oral capsule once daily with morning meal for 6 weeks<br>|
| Placebo Comparator: placebo<br> | Other: placebo<br>* matched placebo orally for 6 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in patient's assessment of arthritis pain according to visual analogue scale (VAS) |  | Week 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vital signs |  | Weeks 2 and 6 | 
| Physical examination |  | Week 6 | 
| Laboratory test results |  | Week 6 | 
| Adverse events |  | Weeks 2 and 6 | 
| Change from baseline in patient's and physician's global assessment of pain |  | Weeks 2 and 6 | 
| Pain Satisfaction Scale |  | Days 1-7 | 
| Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index |  | Week 6 | 
| Patient Health Questionnaire (PHQ-9) |  | Week 6 | 
| Change from baseline in patient's assessment of arthritis pain according to VAS |  | Week 2 |
Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study

Study Overview
=================
Brief Summary
-----------------
This study is an examination of high risk young women, 15-24 years of age, who initiate first time use of vaginal ring, oral contraceptives, contraceptive path, or Depo-provera.

Detailed Description
-----------------
Approximately 1600 young women will be enrolled in a 12 month, observation study of their contraceptive use. They will complete surveys at baseline, 3, 6 and 12 months. They will also undergo pregnancy testing at baseline, 6 and 12 month visits. The study is examining such things are the relationship between partnerships, parental and peer influences, and contraceptive choice; Factors associated with long term continuation of contraceptive methods; Attributes of new hormonal contraceptive associated with user satisfaction and long-term continuation; And the extent to which high-risk women who use these methods are also condom users and determine the characteristics of these users.

Official Title
-----------------
Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - 15-24 years old, English or spanish speaking, Starting ring, pill, patch, or Depo for first time, Sexually active, Single, Not pregnant, Living in Bay Area for next 12 months Exclusion Criteria: Past user of method, Married, Pregnant, Moving out of area, Not sexually active

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 24 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, hormonal contraception
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib

Study Overview
=================
Brief Summary
-----------------
Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.

Detailed Description
-----------------
As above.

Official Title
-----------------
Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib

Conditions
-----------------
Cholangiocarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib. Exclusion Criteria: Not specified.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Unresectable/metastatic cholangiocarcinoma, Cancer, Chart Review